Glenn Whaley - 29 Jun 2026 Form 4 Insider Report for IMMUNIC, INC. (IMUX)

Reporting relationship: Chief Financial Officer
Issuer ticker: IMUX
Reported as of: 29 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jun 2026, 16:31:25 UTC
Prior SEC filing: 18 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Glenn Whaley

Key filing fact

Glenn Whaley filed Form 4 for IMMUNIC, INC. (IMUX) on 29 Jun 2026.

Key facts

This page summarizes Glenn Whaley's Form 4 filing for IMMUNIC, INC. (IMUX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 29 Jun 2026, 16:31.

Change

Previous filing in this sequence was filed on 18 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001724623 Primary reporting owner

Whaley Glenn

Relationship: Chief Financial Officer
Address: 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK
Signature: /s/ Glenn Whaley
Signature date: 29 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMUX transaction Derivative

Stock Option

Award

Transaction value
Shares: +120,000
Change %
Price: $0.000000^*
Shares after: 120,000
Date: 29 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 120,000
Exercise price: $11.60
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents options to purchase shares of common stock conditionally approved by the Board of Directors, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

Footnote F2

The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.